PL2807153T3 - Związki heterocykliczne i sposoby ich zastosowania - Google Patents
Związki heterocykliczne i sposoby ich zastosowaniaInfo
- Publication number
- PL2807153T3 PL2807153T3 PL13741446T PL13741446T PL2807153T3 PL 2807153 T3 PL2807153 T3 PL 2807153T3 PL 13741446 T PL13741446 T PL 13741446T PL 13741446 T PL13741446 T PL 13741446T PL 2807153 T3 PL2807153 T3 PL 2807153T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900286A AU2012900286A0 (en) | 2012-01-25 | "Methods of treatment or prophylaxis" | |
| EP13741446.2A EP2807153B1 (en) | 2012-01-25 | 2013-01-25 | Heterocyclic compounds and methods for their use |
| PCT/AU2013/000061 WO2013110134A1 (en) | 2012-01-25 | 2013-01-25 | Heterocyclic compounds and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2807153T3 true PL2807153T3 (pl) | 2020-09-07 |
Family
ID=48872832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13741446T PL2807153T3 (pl) | 2012-01-25 | 2013-01-25 | Związki heterocykliczne i sposoby ich zastosowania |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150011565A1 (pl) |
| EP (1) | EP2807153B1 (pl) |
| JP (2) | JP6258867B2 (pl) |
| CN (1) | CN104470903B (pl) |
| AU (1) | AU2013202973C9 (pl) |
| CA (1) | CA2861231C (pl) |
| ES (1) | ES2798289T3 (pl) |
| NZ (1) | NZ627560A (pl) |
| PL (1) | PL2807153T3 (pl) |
| PT (1) | PT2807153T (pl) |
| WO (1) | WO2013110134A1 (pl) |
| ZA (1) | ZA201405255B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2620528T3 (es) | 2011-06-22 | 2017-06-28 | Purdue Pharma Lp | Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos |
| PT2800738T (pt) | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| US20150011565A1 (en) * | 2012-01-25 | 2015-01-08 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic Compounds and Methods For Their Use |
| US9714224B2 (en) | 2013-07-08 | 2017-07-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| JP6330040B2 (ja) | 2013-07-22 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体 |
| WO2015063709A1 (en) * | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
| EP3245198B1 (en) | 2015-01-13 | 2020-03-11 | Novartis AG | Pyrrolidine derivatives as angiotensin ii type 2 antagonists |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| PT3245203T (pt) | 2015-01-15 | 2019-02-08 | Idorsia Pharmaceuticals Ltd | Derivados de hidroxialquil-piperazina como modeladores do recetor cxcr3 |
| US10308628B2 (en) | 2015-03-12 | 2019-06-04 | Novartis Ag | Heterocyclic compounds and methods for their use |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| WO2019040105A2 (en) * | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES |
| WO2019118973A1 (en) | 2017-12-15 | 2019-06-20 | Inthera Bioscience AG | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400511A (en) * | 1982-05-07 | 1983-08-23 | American Home Products Corporation | 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids |
| US5116842A (en) * | 1989-05-18 | 1992-05-26 | Glaxo Group Limited | Chemical compounds |
| US5292726A (en) * | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| US5348955A (en) * | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| JP4278008B2 (ja) * | 1996-08-23 | 2009-06-10 | 興和株式会社 | ジアミド化合物及びこれを含有する医薬 |
| ES2224408T3 (es) * | 1997-06-17 | 2005-03-01 | Schering Corporation | Compuestos de benzopiridocicloheptano utiles para la inhibicion de la farnesil-proteina-transferasa. |
| US5968938A (en) * | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
| US6951862B2 (en) * | 1998-06-30 | 2005-10-04 | Neuromed Technologies, Inc. | Calcium channel blockers comprising two benzhydril moieties |
| US20060084660A1 (en) * | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
| US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| PL374860A1 (pl) * | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Podstawione pochodne heterocykliczne korzystne jako środki przeciwko cukrzycy i otyłości i sposób ich stosowania |
| DE10309005A1 (de) * | 2003-03-01 | 2004-09-09 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Dipetidyl Peptidase (DPPIV) und Neurale Endopeptidase (NEP) inhibieren |
| AU2005231872A1 (en) * | 2004-04-09 | 2005-10-20 | Neuromed Pharmaceuticals Ltd. | Diarylamine derivatives as calcium channel blockers |
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| WO2006086609A2 (en) * | 2005-02-10 | 2006-08-17 | Axys Pharmaceuticals, Inc. | Inhibitors of tryptase |
| US20070049578A1 (en) * | 2005-08-24 | 2007-03-01 | Astrazeneca Ab | Cinnamamide compounds as metabotropic glutamate receptor antagonists |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| AU2007229322B2 (en) | 2006-03-20 | 2012-04-05 | Novartis Ag | Method of treatment or prophylaxis inflammatory pain |
| CA2651811A1 (en) * | 2006-05-11 | 2007-11-22 | Neuromed Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| JP2008031064A (ja) * | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| CN102131810B (zh) | 2008-06-25 | 2014-02-26 | 百时美施贵宝公司 | 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类 |
| CA2787173C (en) | 2010-01-19 | 2018-05-01 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| PT2800738T (pt) | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| US20150011565A1 (en) * | 2012-01-25 | 2015-01-08 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic Compounds and Methods For Their Use |
| CN104470930B (zh) | 2012-01-25 | 2017-02-22 | 诺华股份有限公司 | 杂环化合物和它们的使用方法 |
-
2013
- 2013-01-25 US US14/373,355 patent/US20150011565A1/en not_active Abandoned
- 2013-01-25 PL PL13741446T patent/PL2807153T3/pl unknown
- 2013-01-25 EP EP13741446.2A patent/EP2807153B1/en active Active
- 2013-01-25 JP JP2014553581A patent/JP6258867B2/ja active Active
- 2013-01-25 NZ NZ627560A patent/NZ627560A/en unknown
- 2013-01-25 ES ES13741446T patent/ES2798289T3/es active Active
- 2013-01-25 PT PT137414462T patent/PT2807153T/pt unknown
- 2013-01-25 AU AU2013202973A patent/AU2013202973C9/en active Active
- 2013-01-25 WO PCT/AU2013/000061 patent/WO2013110134A1/en not_active Ceased
- 2013-01-25 CA CA2861231A patent/CA2861231C/en active Active
- 2013-01-25 CN CN201380016259.9A patent/CN104470903B/zh active Active
-
2014
- 2014-07-17 ZA ZA2014/05255A patent/ZA201405255B/en unknown
-
2016
- 2016-05-09 US US15/149,641 patent/US9708275B2/en active Active
-
2017
- 2017-10-25 JP JP2017205744A patent/JP2018076297A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013202973C1 (en) | 2016-11-24 |
| CA2861231A1 (en) | 2013-08-01 |
| NZ627560A (en) | 2016-08-26 |
| WO2013110134A1 (en) | 2013-08-01 |
| CN104470903B (zh) | 2017-02-22 |
| ZA201405255B (en) | 2019-04-24 |
| US9708275B2 (en) | 2017-07-18 |
| EP2807153B1 (en) | 2020-03-25 |
| US20150011565A1 (en) | 2015-01-08 |
| JP2015504900A (ja) | 2015-02-16 |
| PT2807153T (pt) | 2020-06-18 |
| ES2798289T3 (es) | 2020-12-10 |
| HK1201533A1 (en) | 2015-09-04 |
| EP2807153A4 (en) | 2015-06-10 |
| AU2013202973B9 (en) | 2016-11-24 |
| CA2861231C (en) | 2021-04-13 |
| CN104470903A (zh) | 2015-03-25 |
| JP6258867B2 (ja) | 2018-01-10 |
| AU2013202973B2 (en) | 2016-06-02 |
| US20160257656A1 (en) | 2016-09-08 |
| JP2018076297A (ja) | 2018-05-17 |
| AU2013202973C9 (en) | 2016-12-22 |
| EP2807153A1 (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405253B (en) | Heterocyclic compounds and methods for their use | |
| ZA201401434B (en) | Heterocyclic compounds and uses thereof | |
| IL230536A0 (en) | Heterocyclic compounds and their uses | |
| EP2678016A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| SG10201609940RA (en) | Compounds and their methods of use | |
| PL2920149T3 (pl) | Związki 3-aminocykloalkilowe jako inhibitory ror-gamma-t oraz ich zastosowania | |
| AP2015008591A0 (en) | Heterocyclic compounds | |
| ZA201405257B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| EP2832734A4 (en) | HETEROCYCLIC COMPOUND | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| AP3611A (en) | Heterocyclic compounds and their uses | |
| EP2782571A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| PL2882708T3 (pl) | Nowe związki i ich zastosowania | |
| GB201213726D0 (en) | Novel compounds and their use | |
| GB201206973D0 (en) | New compounds and uses | |
| GB201207075D0 (en) | New compounds and uses | |
| GB201206055D0 (en) | New compounds and uses | |
| GB201214749D0 (en) | Compounds and their uses | |
| GB201202400D0 (en) | Nitrogen-containing heterocyclic compounds |